Mind + Muscle

technical minds + legal muscle


dig deep

Biosimilar Patents May Be More Vulnerable Than Pharma Patents, but Exclusivity Provisions, Testing Hurdles Could Curb Initial Cases

  • 11.05.10
  • Sasha B. Coffiner
  • Pharmawire

In this article, Timothy Shea comments on the potential patent challenges for biosimilars including a higher barrier for entry for companies seeking to launch biosimilars because of the clinical trials required, the 12 year data exclusivity provisions and the manufacturing challenges for biologics. Download the attached PDF to read the full article.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.